Navigation Links
American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
Date:11/19/2009

BLAUVELT, N.Y., Nov. 19 /PRNewswire/ -- Dr. Mate Hidvegi, inventor of Avemar fermented wheat germ extract, responds to a press release issued on November 17 by Biropharma Kft, discrediting the Hungarian company for making false and self-serving statements about its U.S. competitor American BioSciences.

Dr. Hidvegi stated from his office in Budapest, Hungary:

"The Biropharma claim that research on Avemar does not apply to AveULTRA, www.aveultra.com, is misleading. Avemar has always been manufactured according to methods which I developed and patented. American BioSciences utilizes processes covered by my most recent pending patent. State of the art technology more precisely controls process times and temperatures creating a better quality fermented wheat germ extract. Independent analysis shows that Avemar made by Biropharma and sold under the brand name Ave(TM) and Avemar made by American BioSciences and sold under the brand name AveULTRA, are virtually identical, confirmed by the technique of HPLC finger printing. Furthermore, independent comparison by biological assays in both cell lines and animal models shows the American BioSciences product has superior effects," he said. According to Dr. Hidvegi, these data are being prepared for publication in a peer-reviewed scientific journal.

AveULTRA, newly introduced by American BioSciences, contains the same amount of Avemar fermented wheat germ actives per daily use packet as Ave and is three times more concentrated, with 99 percent less non-active ingredients and no sugar. AveULTRA supports cell metabolic regulation, promotes immune system modulation, and maintains healthy cellular and humoral (Th1/Th2) immune balance. It promotes optimal NK cell targeting ability and the coordinated response of macrophages, B-cells and T-Cells.

"AveULTRA is a huge improvement over the original Ave
'/>"/>

SOURCE American BioSciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. American Heart Association Late-Breaking Clinical Trial Report: New Reversible Antiplatelet Drug no More Effective Than Irreversible One in PCI
2. Viron to Present Data from Phase II Trial at American Heart Association Conference
3. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
4. Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
5. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
6. Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society
7. American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience
8. American Oriental Bioengineering Announces September Investor Conferences Participation
9. American Scientific Resources To Be Exclusive Seller of Worlds Only FDA Approved Home Needle Destruction Device
10. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
11. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... According to new market research report "Data ... Enterprise, Telecom), by Design Types (Electrical, Mechanical), and ... 3, Tier 4) - Global Forecast to 2019", ... Center Construction Market into various segments with an ... report also identifies the factors driving this market, ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in ... announced that its Board of Directors has appointed ... President and member of the Board effective immediately. ... expanded responsibilities within the company, including further developing ... commercialization, manufacturing and finance. , Dr. Carol ...
(Date:10/25/2014)... -- RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or "RegeneRx") ... Symposium on Thymosins in Health and Disease in ... thymosin beta 4 (TB4) linked with rhodamine (a fluorescent ... a rodent model of stroke, it was visualized outside ... functional tissue of the brain).   The leakage of TB4 ...
(Date:10/22/2014)... -- Research and Markets has announced ... Market (Product types, Application, Technology, End User and ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... offering. This new report titled, ... and Geography) Global Size, Industry Analysis, Trends, Opportunities, ...
Breaking Biology Technology:Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3
... and biochemistry at The University of Texas at Austin, ... with Professor William Moerner of Stanford University. , The ... Tamir, was given to the two scientists for their ... and imaging. , The $100,000 prize will be presented ...
... service revenue of $238.7 million grows 32% year-over-year, - Operating ... - Backlog increases 41% ... - Net quarterly book-to-burn ratio equates ... PRXL ) today announced its financial results for the,second quarter ended ...
... of Family Cord Blood Banks, LOS ANGELES, ... of California Cryobank, today announced that its co-founder ... appointed to the Department,of Health and Human Services, ... on Blood Stem Cell Transplantation,(ACBSCT). Through his appointment, ...
Cached Biology Technology:PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 2PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 3PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 4PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 5PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 6PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 7PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 8PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 9PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 10Dr. Charles A. Sims of California Cryobank's Family Cord Blood Services Named to National Stem Cell Advisory Council 2Dr. Charles A. Sims of California Cryobank's Family Cord Blood Services Named to National Stem Cell Advisory Council 3
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... is available in German . ... sperms every day in order to reproduce? And why are ... topic of the latest issue of the research journal ... evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has compiled ... not unusual for a female to copulate with several males ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... A new grant from the National Institute of Biomedical ... of Health (NIH), will provide funding for University of ... novel bioreactor system that will control mechano-electrochemical environment for ... properties of engineered tissues. The two-year, $735,000 grant will ...
... Il. A key statistic that consumer groups and ... national rankings can be misleading, researchers report in a new ... number above 1.0 indicates a hospital had more deaths than ... were fewer than the expected number of deaths. The ...
... Aquaculture, once a fledgling industry, now accounts for 50 percent ... by an international team of researchers. And while the industry ... significant strain on marine resources by consuming large amounts of ... authors conclude. Their findings are published in the Sept. 7 ...
Cached Biology News:University of Miami receives NIH grant to support novel technology for tissue engineering 2Treating bone loss in breast cancer survivors 2Half of the fish consumed globally is now raised on farms, study finds 2Half of the fish consumed globally is now raised on farms, study finds 3
ANTI GELSOLIN...
...
... is intended for the derivation of ... in serum-free conditions. ... Clonal Grade Medium Basal Medium ... Trypsin Solution Gelatin Solution Complete Freezing ...
Template and primers for preparation of internal control spots...
Biology Products: